These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35456626)

  • 1. Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial.
    Drevin G; Briet M; Bazzoli C; Gyan E; Schmidt A; Dombret H; Orvain C; Giltat A; Recher C; Ifrah N; Guardiola P; Hunault-Berger M; Abbara C
    Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979).
    Callies S; de Alwis DP; Mehta A; Burgess M; Aarons L
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):39-48. PubMed ID: 15045528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.
    Dumont C; Mentré F; Gaynor C; Brendel K; Gesson C; Chenel M
    Clin Pharmacokinet; 2013 Jan; 52(1):43-57. PubMed ID: 23212609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia.
    Pea F; Russo D; Michieli M; Damiani D; Fanin R; Michelutti A; Michelutti T; Piccolrovazzi S; Baccarani M; Furlanut M
    Clin Pharmacokinet; 2003; 42(9):851-62. PubMed ID: 12882589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients.
    Robert J; Rigal-Huguet F; Hurteloup P
    Hematol Oncol; 1992; 10(2):111-6. PubMed ID: 1592361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol.
    Hempel G; Relling MV; de Rossi G; Stary J; De Lorenzo P; Valsecchi MG; Barisone E; Boos J; Pieters R
    Pediatr Blood Cancer; 2010 Mar; 54(3):355-60. PubMed ID: 19731319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia.
    Oliveira ML; Rocha A; Nardotto GHB; Pippa LF; Simões BP; Lanchote VL
    J Pharm Biomed Anal; 2020 Nov; 191():113576. PubMed ID: 32889347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of daunorubicin and its main metabolites in plasma, urine and leukaemic cells in patients with acute myeloblastic leukaemia.
    Paul C; Baurain R; Gahrton G; Peterson C
    Cancer Lett; 1980 Jun; 9(4):263-9. PubMed ID: 6930988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid chromatographic determination of daunorubicin and daunorubicinol in plasma from leukemic patients.
    Eksborg S; Ehrsson H; Andersson B; Beran M
    J Chromatogr; 1978 Jun; 153(1):211-8. PubMed ID: 659557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group.
    Thompson P; Wheeler HE; Delaney SM; Lorier R; Broeckel U; Devidas M; Reaman GH; Scorsone K; Sung L; Dolan ME; Berg SL
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):831-8. PubMed ID: 25119182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia.
    Varatharajan S; Panetta JC; Abraham A; Karathedath S; Mohanan E; Lakshmi KM; Arthur N; Srivastava VM; Nemani S; George B; Srivastava A; Mathews V; Balasubramanian P
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1051-1058. PubMed ID: 27738808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia.
    Krogh-Madsen M; Bender B; Jensen MK; Nielsen OJ; Friberg LE; Honoré PH
    Cancer Chemother Pharmacol; 2012 May; 69(5):1155-63. PubMed ID: 22212298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat.
    Cusack BJ; Young SP; Vestal RE; Olson RD
    Cancer Chemother Pharmacol; 1997; 39(6):505-12. PubMed ID: 9118462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat.
    Cusack BJ; Young SP; Olson RD
    Cancer Chemother Pharmacol; 1995; 35(3):213-8. PubMed ID: 7805179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia.
    Bellott R; Auvrignon A; Leblanc T; Pérel Y; Gandemer V; Bertrand Y; Méchinaud F; Bellenger P; Vernois J; Leverger G; Baruchel A; Robert J
    Cancer Chemother Pharmacol; 2001; 47(1):15-21. PubMed ID: 11221955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
    Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
    J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
    Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C
    Ther Drug Monit; 2007 Oct; 29(5):626-31. PubMed ID: 17898654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.
    Lancet JE; Uy GL; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Faderl S; Cortes JE
    Lancet Haematol; 2021 Jul; 8(7):e481-e491. PubMed ID: 34171279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia.
    Bogason A; Quartino AL; Lafolie P; Masquelier M; Karlsson MO; Paul C; Gruber A; Vitols S
    Br J Clin Pharmacol; 2011 Apr; 71(4):514-21. PubMed ID: 21204910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPLC determination of daunorubicin and daunorubicinol in human plasma.
    Hulhoven R; Desager JP
    Biomedicine; 1977 Apr; 27(3):102-4. PubMed ID: 890014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.